ARTICLE | Company News
FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine
September 15, 2018 12:20 AM UTC
FDA approved Ajovy fremanezumab-vfrm from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to prevent migraine in adults. The mAb targeting the calcitonin gene-related peptide ligand is the second in its class approved in the indication.
Teva said it expects monthly and quarterly injectable doses of Ajovy to be available within two weeks at a wholesale acquisition cost (WAC) of $575 and $1,725, respectively...
BCIQ Target Profiles